Literature DB >> 28109079

Silencing of Ribosomal Protein L34 (RPL34) Inhibits the Proliferation and Invasion of Esophageal Cancer Cells.

Huijie Fan, Jing Li, Yongxu Jia, Jingjing Wu, Long Yuan, Mingjun Li, Jiangqi Wei, Benling Xu.   

Abstract

Ribosomal protein L34 (RPL34) belongs to the L34E family of ribosomal proteins and contains a zinc finger motif. Aberrant expression of RPL34 has been reported in several human malignancies. However, the precise role and potential underlying mechanisms of RPL34 in human esophageal cancer remain largely unknown. Thus, the objective of this study was to investigate the role of RPL34 in esophageal cancer progression. Our results showed that the expression of RPL34 at both the mRNA and protein levels was frequently upregulated in esophageal cancer cell lines. Knockdown of RPL34 efficiently inhibited esophageal cancer cell proliferation, migration, and invasion in vitro. Mechanistically, knockdown of RPL34 significantly downregulated the protein expression level of p-PI3K and p-Akt in esophageal cancer cells. Finally, knockdown of RPL34 attenuated tumor growth in nude mice. In conclusion, our study revealed that RPL34 functions as an oncogene that modulates the proliferation and metastasis of esophageal cancer cells, in part, by the inactivation of the PI3K/Akt signaling pathway. Thus, these findings suggest that RPL34 may serve as a potential therapeutic target for the treatment of esophageal cancer.

Entities:  

Mesh:

Substances:

Year:  2017        PMID: 28109079     DOI: 10.3727/096504016X14830466773541

Source DB:  PubMed          Journal:  Oncol Res        ISSN: 0965-0407            Impact factor:   5.574


  13 in total

1.  Diagnostic and prognostic implications of ribosomal protein transcript expression patterns in human cancers.

Authors:  James M Dolezal; Arie P Dash; Edward V Prochownik
Journal:  BMC Cancer       Date:  2018-03-12       Impact factor: 4.430

2.  Quercetin Inhibits the Proliferation and Aflatoxins Biosynthesis of Aspergillus flavus.

Authors:  Xiu-Mei Li; Zhong-Yuan Li; Ya-Dong Wang; Jin-Quan Wang; Pei-Long Yang
Journal:  Toxins (Basel)       Date:  2019-03-09       Impact factor: 4.546

3.  Biological effect of ribosomal protein L32 on human breast cancer cell behavior.

Authors:  Lu Xu; Lintao Wang; Chaojun Jiang; Qiannan Zhu; Rui Chen; Jue Wang; Shui Wang
Journal:  Mol Med Rep       Date:  2020-07-06       Impact factor: 2.952

4.  RPL34-AS1-induced RPL34 inhibits cervical cancer cell tumorigenesis via the MDM2-P53 pathway.

Authors:  Yuanhang Zhu; Chenchen Ren; Dongyuan Jiang; Li Yang; Yannan Chen; Feiyan Li; Baojin Wang; Yali Zhang
Journal:  Cancer Sci       Date:  2021-03-18       Impact factor: 6.716

Review 5.  microRNAs Mediated Regulation of the Ribosomal Proteins and its Consequences on the Global Translation of Proteins.

Authors:  Abu Musa Md Talimur Reza; Yu-Guo Yuan
Journal:  Cells       Date:  2021-01-08       Impact factor: 6.600

6.  Dual Inhibition of DKC1 and MEK1/2 Synergistically Restrains the Growth of Colorectal Cancer Cells.

Authors:  Guangyan Kan; Ziyang Wang; Chunjie Sheng; Gong Chen; Chen Yao; Yizhi Mao; Shuai Chen
Journal:  Adv Sci (Weinh)       Date:  2021-03-15       Impact factor: 16.806

Review 7.  Ribosomal proteins and human diseases: molecular mechanisms and targeted therapy.

Authors:  Jian Kang; Natalie Brajanovski; Keefe T Chan; Jiachen Xuan; Richard B Pearson; Elaine Sanij
Journal:  Signal Transduct Target Ther       Date:  2021-08-30

8.  The Ribosomal Protein L28 Gene Induces Sorafenib Resistance in Hepatocellular Carcinoma.

Authors:  Yi Shi; Xiaojiang Wang; Qiong Zhu; Gang Chen
Journal:  Front Oncol       Date:  2021-07-08       Impact factor: 6.244

Review 9.  The nucleolus, an ally, and an enemy of cancer cells.

Authors:  Dariusz Stępiński
Journal:  Histochem Cell Biol       Date:  2018-08-13       Impact factor: 4.304

10.  Knockdown of RPL34 suppresses osteosarcoma cell proliferation likely through EIF3/FAU signaling pathway.

Authors:  Piwei Huang; Jinmin Zhao; Mitra Fowdur; Yun Liu; Hao Wu; Maolin He
Journal:  Transl Cancer Res       Date:  2019-06       Impact factor: 1.241

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.